Literature DB >> 28031199

Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.

Pier Giorgio Cojutti1,2, Virginia Ramos-Martin3, Isabella Schiavon4, Paolo Rossi4, Massimo Baraldo1,2, William Hope3, Federico Pea5,2.   

Abstract

A retrospective study was conducted in a large sample of acutely hospitalized older patients who underwent therapeutic drug monitoring during levofloxacin treatment. The aim was to assess the population pharmacokinetics (popPK) and pharmacodynamics of levofloxacin among older patients. PopPK and Monte Carlo simulation were performed to define the permissible doses in older patients according to various degrees of renal function. Classification and regression tree (CART) analysis was used to detect the cutoff 24-hour area under the concentration-time curve (AUC24)/MIC ratio that best correlated with the clinical outcome. The probability of target attainment (PTA) of this value was calculated against different pathogens. A total of 168 patients were included, and 330 trough and 239 peak concentrations were used for the popPK analysis. Creatinine clearance (CrCL) was the only covariate that improved the model fit (levofloxacin CL = 0.399 + 0.051 × CrCLCKD-EPI [creatinine clearance estimated by means of the chronic kidney disease epidemiology]). Drug doses ranged between 500 mg every 48 h and 500 mg every 12 h in relation to different renal functions. The identified cutoff AUC24/MIC ratio (≥95.7) was the only covariate that correlated with a favorable clinical outcome in multivariate regression analysis (odds ratio [OR], 20.85; 95% confidence interval [CI], 1.56 to 186.73). PTAs were optimal (>80%) against Escherichia coli and Haemophilus influenzae, borderline against Staphylococcus aureus, and suboptimal against Pseudomonas aeruginosa The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of ≤0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk. Conversely, the addition of another active antimicrobial should be considered whenever treating infections caused by less susceptible pathogens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  efficacy; fluoroquinolones; personalized therapy; population pharmacokinetics; safety

Mesh:

Substances:

Year:  2017        PMID: 28031199      PMCID: PMC5328580          DOI: 10.1128/AAC.02134-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

2.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Population pharmacokinetics of levofloxacin in Korean patients.

Authors:  Sungmin Kiem; Sung-Mun Ryu; Yun-Mi Lee; Jerome J Schentag; Yang-Wook Kim; Hyeon-Kuk Kim; Hang-Jae Jang; Yong-Don Joo; Kyubok Jin; Jae-Gook Shin; Jong-Lyul Ghim
Journal:  J Chemother       Date:  2016-08       Impact factor: 1.714

4.  GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly.

Authors:  Martin Flamant; Jean-Philippe Haymann; Emmanuelle Vidal-Petiot; Emmanuel Letavernier; Christine Clerici; Jean-Jacques Boffa; François Vrtovsnik
Journal:  Am J Kidney Dis       Date:  2012-08-30       Impact factor: 8.860

5.  Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; F A Wong; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.

Authors:  J Child; D Mortiboy; J M Andrews; A T Chow; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  Adverse drug reactions in special populations - the elderly.

Authors:  E A Davies; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2015-05-22       Impact factor: 4.335

Review 8.  Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.

Authors:  Jerome J Schentag; Alison K Meagher; Alan Forrest
Journal:  Ann Pharmacother       Date:  2003-10       Impact factor: 3.154

Review 9.  Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?

Authors:  Monique R Bidell; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2016-06-11       Impact factor: 4.705

10.  Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.

Authors:  Mario Furlanut; Loris Brollo; Emilio Lugatti; Elena Di Qual; Flavio Dolcet; Giovanni Talmassons; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

View more
  3 in total

1.  Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study.

Authors:  Dzenefa Alihodzic; Sebastian G Wicha; Otto R Frey; Christina König; Michael Baehr; Dominik Jarczak; Stefan Kluge; Claudia Langebrake
Journal:  Pharmaceutics       Date:  2022-04-29       Impact factor: 6.525

Review 2.  Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.

Authors:  Oskar Estradé; Valvanera Vozmediano; Nerea Carral; Arantxa Isla; Margarita González; Rachel Poole; Elena Suarez
Journal:  Antibiotics (Basel)       Date:  2022-05-11

3.  Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients.

Authors:  Eko Setiawan; Mohd-Hafiz Abdul-Aziz; Menino Osbert Cotta; Susaniwati Susaniwati; Heru Cahjono; Ika Yunita Sari; Tjipto Wibowo; Ferdy Royland Marpaung; Jason A Roberts
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.